Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].
A Özkan
,
E Kapiteijn
,
F van den Bos
,
M J B Aarts
,
F W P J van den Berkmortel
,
C U Blank
,
M Bloem
,
W A M Blokx
,
M J Boers-Sonderen
,
J J Bonenkamp
,
A J M van den Eertwegh
,
J W B de Groot
,
J B Haanen
,
C E Holtslag
,
G A P Hospers
,
D Piersma
,
R S van Rijn
,
A M Stevense-den Boer
,
K P M Suijkerbuijk
,
A A M van der Veldt
,
G Vreugdenhil
,
M W J M Wouters
,
J E A Portielje
,
N A de Glas
More about this publication
European journal of cancer (Oxford, England : 1990)
Volume
216
Pages
115194
Publication date
05-02-2025
Full text links
Publisher website (DOI)
10.1016/j.ejca.2024.115194
Europe PubMed Central
39732138
Pubmed
39732138